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Introduction
============

The disease of obesity and its related comorbid conditions represent the most significant public health threat of our time \[[@REF1]\]. Weight loss surgery has been proven to be the most effective and consistent treatment for patients seeking long-term weight loss and has demonstrated a significant impact on patient longevity \[[@REF2],[@REF3]\]. Currently, several types of procedures are employed that vary in the degree of restriction and malabsorption \[[@REF4]\]. The laparoscopic adjustable gastric band (LAGB) obtained FDA approval in the United States in 2001. Over the past 18 years, it has been utilized as a purely restrictive procedure for the treatment of obesity with reasonable weight loss results \[[@REF5]-[@REF7]\]. With more indwelling LAGBs, the potential for long-term complications requiring surgical intervention has become evident \[[@REF8]-[@REF12]\]. Predictive factors of these complications and reoperative rates have not fully been determined in the American patient population. The specific aims of this study are to provide clinicians and patients with incidence rates of long-term complications and predictive factors requiring surgical reintervention after LAGB.

Materials and methods
=====================

Institutional review board (IRB) approval to conduct the study was obtained at a university affiliated tertiary care center with an American Society of Metabolic and Bariatric Surgery (ASMBS) Center of Excellence designation and subsequent Metabolic and Bariatric Surgery Accreditation and Quality Improvement Program (MBSAQIP) accreditation. A retrospective chart review was performed on 200 consecutive patients undergoing LAGB from 2005 to 2011. Data were collected through March 2015. Patients were considered lost to follow-up if no data were available at the one-year appointment. Data included age, gender, preoperative body mass index (BMI), excess body weight (EBW), % excess body weight lost (%EWL) and preoperative comorbidities: diabetes mellitus (DM), hypertension (HTN), obstructive sleep apnea (OSA), hyperlipidemia (HLD) and gastroesophageal reflux disease (GERD). The primary endpoint was need for surgical intervention due to a complication from LAGB. Complications resulting in reintervention were recorded and classified as band slippage/prolapse, weight loss failure, band intolerance, port/tube complications and gastric erosion. Reinterventions were further analyzed for conversion to an alternative bariatric procedure (laparoscopic Roux-en-Y gastric bypass \[LRYGB\] or laparoscopic sleeve gastrectomy \[LSG\]). Compliance with diet and exercise programs was also reported.

Data were tabulated in Excel, and analyses were performed using the SPSS Statistics software (IBM Corp., Armonk, NY). Pearson's chi-squared test for association was used to calculate p-values if expected cell frequency was greater than or equal 5. If any expected cell frequency was greater than 5, Fisher's exact method was employed. The Anderson-Darling statistic compared several distributions (exponential, normal and three-parameter Weibull) to determine fit. P-values from the Anderson-Darling Normality test determined if two-independent sample t-test or Mann-Whitney's test was employed. A p-value of \<0.05 was defined as statistically significant.

Results
=======

A total of 200 patients were studied with a mean follow-up of 46 months (range = 2-109) (Table [1](#TAB1){ref-type="table"}). Of all participants, six (3%) patients did not have 12-month data available and were considered lost to follow-up and excluded from the study. Noted in the series were three deaths, none of which occurred within the 12-month initial operative period and none were associated with band complications.

###### Descriptive Statistics of Patients Undergoing LAGB

BMI, body mass index; EBW, excess body weight, LAGB, laparoscopic adjustable gastric banding; Std., standard deviation

  --------------------------- ----------------- -------- --------------
  Variable                    Mean (Std.)       Median   Range
  Months of follow-up         46.53 (±26.84)    44       (2, 109)
  Age                         53.60 (±11.61)    54       (24, 77)
  Preoperative height (in.)   64.20 (±3.00)     64       (57.5, 75)
  Preoperative weight (lbs)   259.33 (±40.35)   252.3    (184, 377.8)
  Preoperative BMI            44.187 (±5.57)    43.05    (35.1, 62.1)
  Preoperative EBW (lbs)      127.16 (±35.56)   121.1    (65, 232)
  Weight at 12 months (lbs)   210.6 (±36.52)    205      (137, 340)
  BMI at 12 months            35.876 (±5.35)    35.2     (24.8, 57.5)
  EBW at 12 months (lbs)      78.78 (±32.19)    74.5     (13, 206)
  --------------------------- ----------------- -------- --------------

Of all participants, 176 patients (90.7%) were female with a mean age of 53.6 years (standard deviation \[SD\] = 11.6, range = 24-77) and the mean preoperative BMI was 44.2 kg/m^2^ (SD = 5.6, range = 35.1-62.1). Patients with preoperative comorbidities (Table [2](#TAB2){ref-type="table"}) included 129 (66.5%) HTN, 94 (48.5%) OSA, 92 (47.4%) GERD and 67 (34.5%) DM. LAGB complications requiring reoperation (Table [3](#TAB3){ref-type="table"}) occurred in 55 (28.4%) patients. Reasons for reintervention included 24 (12.4%) band slippage/prolapses, 19 (9.8%) weight loss failures, five (2.6%) band intolerances, five (2.6%) port/tubing complications and two (1.0%) band erosions.

###### Preoperative Sex, Comorbidities, Compliance and Need for Reintervention

GERD, gastroesophageal reflux disease; OSA, obstructive sleep apnea

  --------------------- -------- ----------------- ------------
  Variable                       No. of Patients   Percentage
  Sex                                               
                        Male     18                9.3%
                        Female   176               90.7%
  Diabetes                                          
                        Yes      67                34.5%
                        No       127               65.5%
  Hypertension                                      
                        Yes      129               66.5%
                        No       65                33.5%
  OSA                                               
                        Yes      94                48.5%
                        No       100               51.5%
  Hyperlipidemia                                    
                        Yes      85                43.8%
                        No       109               56.2%
  GERD                                              
                        Yes      92                47.4%
                        No       102               52.6%
  Exercise compliance                               
                        Yes      90                46.4%
                        No       104               53.6%
  Diet compliance                                   
                        Yes      96                49.5%
                        No       98                50.5%
  Reintervention                                    
                        Yes      55                28.4%
                        No       139               71.6%
  --------------------- -------- ----------------- ------------

 

###### Complications Requiring Reintervention

  -------------------------- ---- ------------
  Complication               n    Percentage
  Band slippage/prolapse     24   12.37%
  Weight loss failure        19   9.79%
  Band intolerance           5    2.58%
  Port/tubing complication   5    2.58%
  Band erosion               2    1.03%
  Total reintervention       55   28.35%
  -------------------------- ---- ------------

Patients who required reintervention (Table [4](#TAB4){ref-type="table"}) had a greater preoperative weight (268.55 lbs vs. 255.69, p \< 0.016), but there was no significant difference in BMI (44.01 vs. 44.64, p = 0.681). These patients were younger (48.20 vs. 55.73, p \< 0.001), had higher 12-month %EWL (44.58% vs. 36.62%, p = 0.002) and were more compliant with diet (Table [5](#TAB5){ref-type="table"}, p = 0.031) and exercise (p = 0.038) than the no intervention group. There was a trend towards lower 12-month BMI in the reintervention group (p = 0.065); however, this did not reach statistical significance. Patients requiring reintervention were less likely to have HTN (49.1% vs. 73.4%, p = 0.001), DM (23.6% vs. 38.8%, p = 0.045) and HLD (30.9% vs. 48.2%, p = 0.05) compared with the no reintervention group. There was no statistically significant difference in sex, preoperative OSA or GERD between the groups.

###### Descriptive Statistics Between LAGB Patient's Not Requiring and Requiring Reintervention

AD, Anderson-Darling; BMI, body mass index; EBW, excess body weight; LABG, laparoscopic adjustable gastric banding; Std., standard deviation

  --------------------------- ----------------------------- ------------------------- -------- ----------------------------- ------------------------- --- ------------------- ----------------------
                              Mean ± Std.                                             Median                                 P-Value                                           
   Variable                   No Reintervention (n = 139)   Reintervention (n = 55)            No Reintervention (n = 139)   Reintervention (n = 55)       AD Normality Test   Mann-Whitney\'s Test
  Age                         55.734 ± 10.76                48.20 ± 12.01                      56                            47                            \<0.005             0.000
  Preoperative weight (lbs)   255.69 ± 41.11                268.55 ± 36.16                     250.8                         262.0                         \<0.005             0.016
  Preoperative BMI            44.01 ± 5.49                  44.64 ± 5.78                       43.3                          42.9                          \<0.005             0.681
  Preoperative EBW (lbs)      124.85 ± 36.24                132.97 ± 33.38                     118.0                         127.4                         \<0.005             0.070
  Weight at 12 months (lbs)   211.33 ± 38.46                208.77 ± 31.34                     205                           205                           \<0.005             0.911
  BMI at 12 months (lbs)      36.35 ± 5.55                  34.69 ± 4.62                       35.7                          34.1                          \<0.005             0.065
  EBW at 12 months (lbs)      80.64 ± 34.05                 74.07 ± 26.64                      75                            68                            \<0.005             0.252
  --------------------------- ----------------------------- ------------------------- -------- ----------------------------- ------------------------- --- ------------------- ----------------------

###### Relative Risk, Risk Difference and Attributable Proportion of Reintervention by Sex, Comorbidities, Exercise and Diet Compliance

CI, confidence interval; GERD, gastroesophageal reflux disease; OSA, obstructive sleep apnea

\*Preventive fraction

  ---------------- -------- ----------------------------- ------------------------- ------------------------ ----------------------- ----------------- -------------------------
  Variable                  No Reintervention (n = 139)   Reintervention (n = 55)   Relative Risk (95% CI)   P-Value (Chi-Squared)   Risk Difference   Attributable Proportion
  Sex                                                                                                                                                   
                   Male     11                            7                         1.43 (0.76-2.67)         0.298                   11.62%            29.87%
                   Female   128                           48                        1.00                                                                
  Diabetes                                                                                                                                              
                   Yes      54                            13                        0.59 (0.34-1.01)         0.045                   -13.67%           41.33%\*
                   No       85                            42                        1.00                                                                
  Hypertension                                                                                                                                         
                   Yes      102                           27                        0.49 (0.31-0.75)         0.001                   -22.15%           51.41%\*
                   No       37                            28                        1.00                                                                
  Hyperlipidemia                                                                                                                                       
                   Yes      67                            17                        0.62 (0.38-1.01)         0.050                   -12.77%           37.62%\*
                   No       72                            37                        1.00                                                                
  OSA                                                                                                                                                   
                   Yes      68                            26                        0.95 (0.61-1.49)         0.836                   -1.34%            4.62%\*
                   No       71                            29                        1.00                                                                
  GERD                                                                                                                                                  
                   Yes      63                            29                        1.24 (0.79-1.94)         0.352                   6.03%             19.13%
                   No       76                            26                        1.00                                                                
  Exercise                                                                                                                                              
                   Yes      58                            32                        1.61 (1.02-2.54)         0.038                   13.44             37.80%
                   No       81                            23                        1.00                                                                
  Diet                                                                                                                                                  
                   Yes      62                            34                        1.65 (1.04-2.63)         0.031                   13.99             39.50%
                   No       77                            21                        1.00                                                                
  ---------------- -------- ----------------------------- ------------------------- ------------------------ ----------------------- ----------------- -------------------------

For the 55 patients undergoing reintervention, 25 (46%) underwent an alternative bariatric procedure (Table [6](#TAB6){ref-type="table"}). These patients tended to have a lower preoperative weight (117.7 vs. 125.71, p = 0.083). There was no statistical significance between preoperative BMI and 12-month %EWL. There was no statistical difference in comorbidities, sex or exercise/diet compliance between these groups (Table [7](#TAB7){ref-type="table"}). The average time to conversion to an alternative bariatric procedure was 55.5 (range = 25.8-87.5) months. The majority of these patients (21) underwent conversion to a LRYGB, while only four patients had an LSG.

###### Descriptive Statistics of Reintervention Patients Undergoing Alternative Bariatric Procedures

AD, Anderson-Darling; BMI, body mass index; EBW, excess body weight; Std., standard deviation

\*Two-independent sample t-test

  --------------------------- --------------------------------- ------------------------------ -------- --------------------------------- ------------------------------ --- ------------------- ----------------------
                              Mean ± Std.                                                      Median                                     P-Value                                                
   Variable                   No Bariatric Procedure (n = 30)   Bariatric Procedure (n = 25)            No Bariatric Procedure (n = 30)   Bariatric Procedure (n = 25)       AD Normality Test   Mann-Whitney\'s Test
  Age                         49.33 ± 11.36                     46.84 ± 12.85                           48.5                              47.0                                0.597               0.454\*
  Preoperative weight (lbs)   125.71 ± 16.62                    117.70 ± 15.41                          125.68                            116.82                              0.030              0.083
  Preoperative BMI            45.95 ± 6.76                      43.06 ± 3.87                            43.7                              42.8                               \<0.005             0.265
  Preoperative EBW (lbs)      64.37 ± 16.08                     55.73 ± 12.78                           62.95                             55.73                               0.017              0.061
  Weight at 12 months (lbs)   94.98 ± 13.75                     94.80 ± 15.11                           92.50                             97.73                               0.071               0.965\*
  BMI at 12 months            34.70 ± 5.18                      34.67 ± 3.96                            33.55                             34.20                               0.100               0.982\*
  EBW at 12 months (lbs)      33.78 ± 12.76                     33.54 ± 11.55                           29.00                             32.73                               0.128               0.943\*
  --------------------------- --------------------------------- ------------------------------ -------- --------------------------------- ------------------------------ --- ------------------- ----------------------

###### Relative Risk, Risk Difference and Attributable Proportion of Bariatric Surgery by Sex, Comorbidities, Exercise and Diet

CI, confidence interval; GERD, gastroesophageal reflux disease; OSA, obstructive sleep apnea

\*Preventive fraction

†Fisher's exact method

  ---------------- -------- ------------------------------- ---------------------------- ----------------------- ----------------------- ----------------- -------------------------
  Variable                  No Bariatric Surgery (n = 30)   Bariatric Surgery (n = 25)   Relative Risk (95%CI)   P-Value (Chi-Squared)   Risk Difference   Attributable Proportion
  Sex                                                                                                                                                       
                   Male     2                               5                            0.86 (0.69-1.07)        0.226†                  -13.33%           14.29%\*
                   Female   28                              20                           1.00                                                               
  Diabetes                                                                                                                                                  
                   Yes      7                               6                            1.03 (0.40-2.67)        0.954                   0.67%             2.78%
                   No       23                              19                           1.00                                                               
  Hypertension                                                                                                                                             
                   Yes      16                              11                           0.83 (0.47-1.44)        0.491                   -9.33%            17.5%\*
                   No       14                              14                           1.00                                                               
  Hyperlipidemia                                                                                                                                           
                   Yes      10                              8                            0.96 (0.45-2.06)        0.916                   -1.33%            4%\*
                   No       20                              17                           1.00                                                               
  OSA                                                                                                                                                       
                   Yes      14                              12                           1.02 (0.59-1.80)        0.921                   1.33%             2.78%
                   No       16                              13                           1.00                                                               
  GERD                                                                                                                                                      
                   Yes      17                              12                           0.85 (0.51-1.42)        0.521                   -8.67%            15.3%\*
                   No       13                              13                           1.00                                                               
  Exercise                                                                                                                                                  
                   Yes      19                              13                           0.82 (0.51-1.31)        0.369                   -11.33            18.9%\*
                   No       11                              12                           1.00                                                               
  Diet                                                                                                                                                      
                   Yes      20                              14                           0.84 (0.55-1.29)        0.418                   -10.67            16%\*
                   No       10                              11                           1.00                                                               
  ---------------- -------- ------------------------------- ---------------------------- ----------------------- ----------------------- ----------------- -------------------------

Discussion
==========

LAGB is known to provide moderate weight loss with an excellent perioperative safety profile \[[@REF5]-[@REF7]\]. Early studies revealed short-term superiority with the LAGB in regards to weight reduction (43-78 %EWL at three years), remission of diabetes and other obesity-related comorbidities compared with medical therapy alone \[[@REF13]-[@REF15]\]. Perioperative mortality was found to be \<0.05% in these studies \[[@REF15]\]. Despite this, as more data became available, LABG showed poor long-term efficacy. Ten-year data from Froylich et al. revealed no improvement in comorbidities and worsening of GERD-related symptoms; 59.4% of the patients had their band removed, and 30% of those went on to have an alternative bariatric procedure \[[@REF16]\]. With other studies reporting high rates of reintervention between 19.2% and 33.1%, bariatric procedures with more durable weight loss outcomes were advocated \[[@REF8],[@REF9],[@REF17]\].

LSG and LRYGB were studied in comparison to the LAGB and found to be superior. LSG and LRYGB showed greater weight loss with improvement or remission of comorbidities compared with LAGB \[[@REF18]-[@REF21]\]. Tice et al. showed superior %EWL (76% vs. 48%) and diabetes resolution (78% vs. 50%) comparing LRYGB and LAGB. Although perioperative complications were higher for LRYGB (9% vs. 5%), LRYGB was associated with fewer long-term reoperations (16% vs. 25%) and higher patient satisfaction \[[@REF19]\]. LRYGB achieved greater weight loss and BMI reduction five years after surgery compared with LAGB \[[@REF20]\]. In the super obese population (BMI \> 50), there was no difference in early complications between LRYGB and LAGB; however, LRYGB was again associated with higher EWL at 12 months (54.7% vs. 31.5%) \[[@REF21]\].

For patients requiring reintervention and seeking further weight loss after LAGB failure, conversion to LSG or LRYGB in a one- or two-stage procedure is feasible \[[@REF22]-[@REF25]\]. Several studies have shown that conversion to another bariatric procedure is safe with low morbidity (1.1%) and mortality (\<1%) \[[@REF24],[@REF25]\]. Both conversion procedures have similar complication rates, hospital stay and early weight loss \[[@REF22]-[@REF25]\]. Additionally, the EWL in converted patients at two years was similar, approximately 60% \[[@REF22],[@REF25]\].

In our study, long-term complications from LAGB leading to surgical reintervention occurred with significant frequency, with more than 28.4% of the patients requiring surgery within a 46-month average follow-up. The most common reason for reintervention was band slippage or prolapse followed closely by weight loss failures. Less common were band intolerances, port/tubing complications and band erosions. Causes for reintervention appear consistent with reported literature; however, direct comparison is hampered by variability in reporting of complications in these studies \[[@REF8],[@REF9],[@REF26]\]. Of the patients who experienced weight loss failure, 84% (n = 16) underwent an alternative bariatric procedure compared with 33% (n = 8) of band slippage/prolapse patients. Only one patient with band intolerance underwent an alternative procedure for severe GERD associated with the LAGB. Of those undergoing an alternative bariatric procedure, 84% (n = 21) elected for LRYGB compared with the LSG (n = 4). While difficult to quantify, there appeared to be a bias towards conversion to LRYGB due to concern of trading one restrictive procedure (LAGB) for another (LSG). Given equivocal two-year %EWL, which is evident in newer literature, this is likely an unfounded concern \[[@REF24],[@REF25]\].

Overall, patients in this study experiencing band complications requiring reintervention were younger, had a higher preoperative weight and less comorbidities (lower rates of DM, HTN and HLD). At 12 months, these patients tended to have a lower %EWL and were statistically significantly more compliant with prescribed diet and exercise routines. Of this reintervention group, those with a lower %EWL at 12 months were more likely to undergo a conversion to an alternative bariatric procedure. These data suggest that in younger, healthier patients who are motivated about weight loss, LAGB may not be the ideal initial procedure as it is associated with higher reintervention rates over time. As 45.5% of this population underwent an alternative bariatric procedure, an LRYGB or LSG may be more satisfactory to meet these patients' long-term weight loss goals.

The limitations of our study include its retrospective nature without randomization or a control group. Some patients were lost to follow-up and may have presented to outside institutions for complication care and therefore could not be accounted. Additionally, no data regarding quality of life or weight loss satisfaction were collected. These factors may also influence a patient's decision when choosing a bariatric procedure.

Conclusions
===========

Although LAGB is not as common as it was a short time ago, the procedure is still performed today and most practicing bariatric surgeons will encounter patients with indwelling bands. Clinicians caring for these patients should be aware of the complications necessitating reoperation and the patient characteristics associated with these complications. LAGB is associated with high long-term complication rates, and our study suggests that alternative bariatric procedures may be more appropriate in younger patients with fewer comorbid conditions who are motivated to lose weight. While LAGB may still have a limited role in a select subset of patients, given the high frequency of potential complications, it should not be presented as the only option within a bariatric program. Our findings may guide clinicians and patients in utilizing alternative bariatric and metabolic procedures which have been shown to have superior efficacy with much lower rates of surgical reintervention.
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